Risks of hepatitis C virus reactivation in a real-life population of oncology patients treated in an academic center

C Boutin(Centre Hospitalier de l’Université de Montréal), Valérie Martel‐Laferrière(Centre Hospitalier de l’Université de Montréal), Stéphane Doucet(Centre Hospitalier de l’Université de Montréal), Jean‐Philippe Adam(Centre Hospitalier de l’Université de Montréal), Dominic Martel(Centre Hospitalier de l’Université de Montréal)
Journal of Oncology Pharmacy Practice
November 2, 2020
10.1177/1078155220969797
Cited by 3

Related Papers

Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Respiratory Medicine|2021|248
Breakthrough Invasive Fungal Infections in Patients With High-Risk Hematological Disorders Receiving Voriconazole and Posaconazole Prophylaxis: A Systematic Review
|Clinical Infectious Diseases|2024|55
Prevalence of legionellosis among adults: A study of community-acquired pneumonia in France
|Infection|1987|50
Update on therapeutic approaches for invasive fungal infections in adults
|Therapeutic Advances in Infectious Disease|2024|36
Comparison of SARS-CoV-2 detection from combined nasopharyngeal/oropharyngeal swab samples by a laboratory-developed real-time RT-PCR test and the Roche SARS-CoV-2 assay on a cobas 8800 instrument
|Journal of Clinical Virology|2020|20